Welcome to our dedicated page for Galera Therapeutics SEC filings (Ticker: GRTX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Galera Therapeutics, Inc. (GRTX) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. These documents offer detailed information on Galera’s clinical-stage biopharmaceutical activities, financial condition, strategic decisions, and changes in trading status.
Galera’s periodic reports, such as Forms 10-K and 10-Q referenced in its press releases, discuss its focus on developing novel, proprietary therapeutics related to radiotherapy and cancer, including historical work on superoxide dismutase mimetics and more recent emphasis on a pan-nitric oxide synthase inhibitor in advanced breast cancer. These filings typically describe research and development expenses, general and administrative costs, net losses, cash and cash equivalents, and risk factors associated with funding needs, regulatory uncertainty, and potential cessation of operations.
Current reports on Form 8-K are especially important for tracking material events. For example, an October 2025 Form 8-K details an Asset Purchase and Sale Agreement under which Biossil Inc. agreed to acquire all of Galera’s right, title, and interest in assets related to avasopasem, rucosopasem, and other dismutase mimetic assets, and to assume related obligations under a royalty agreement, in exchange for an upfront payment and potential future milestone and contingent value right payments. Another Form 8-K notes that Galera’s common stock trades on the OTCQB Market under the symbol GRTX.
Earlier disclosures referenced in company communications include information about the Board’s approval of a Plan of Liquidation and Dissolution, adoption of a limited duration stockholder rights agreement, workforce reductions, and the engagement of financial advisors to review strategic alternatives. Together, these filings document Galera’s transition from a Nasdaq-listed clinical-stage oncology company through strategic review, proposed dissolution, acquisition of Nova Pharmaceuticals, and sale of key assets.
On Stock Titan, AI-powered tools can help interpret Galera’s filings by summarizing complex sections of Forms 10-K and 10-Q, highlighting key terms in material agreements disclosed on Form 8-K, and organizing information about trading status and corporate actions. This allows readers to quickly understand how regulatory filings relate to Galera’s evolving business and the GRTX stock.
Galera Therapeutics, Inc. entered into a letter agreement with Joel Sussman, its Chief Accounting Officer, Treasurer, Secretary, and a named executive officer, establishing retention-based cash bonus payments tied to timely completion and filing of certain company reporting obligations.
Under the agreement, Mr. Sussman may receive up to $250,000 in total retention bonuses. Any retention bonuses paid will reduce, on a dollar-for-dollar basis, any severance otherwise due to him under his existing employment agreement. If his employment is involuntarily terminated without cause, or he resigns for good reason, any unpaid retention bonus will be paid regardless of whether the original conditions are met.
Galera Therapeutics, Inc. (GRTX) president and CEO J. Mel Sorensen, who is also a director, reported an open market sale of company stock. On 11/20/2025, he sold 70,000 shares of common stock at a weighted average price of $0.0201 per share, with individual trades executed between $0.02 and $0.0201. After this transaction, he beneficially owned 195,029 shares of Galera Therapeutics common stock in direct ownership.
GRTX has a Form 144 notice indicating that an affiliate plans to sell up to 70,000 shares of common stock through Raymond James & Associates on the OTC Markets, with an approximate sale date of 11/20/2025 and an aggregate market value of
Galera Therapeutics (OTCQB:GRTX) reported a smaller quarterly loss and a strategic reset. For the quarter ended September 30, 2025, net loss was $1.4 million versus $5.6 million a year ago as operating expenses fell sharply; research and development was $0.1 million and general and administrative was $1.3 million.
Cash and cash equivalents were $4.5 million, with total assets of $5.0 million and a stockholders’ deficit of $149.2 million. A royalty purchase liability of $151.0 million remained on the balance sheet at quarter‑end, and was subsequently assigned to Biossil alongside the sale of the company’s dismutase mimetic assets for $3.5 million in October 2025. Management states that existing cash plus the $3.5 million will fund limited operations for at least twelve months from issuance.
The business has shifted to a pan‑NOS inhibitor program for difficult breast cancers. An investigator‑sponsored Phase 1/2 study at Houston Methodist is funded by an NIH grant, and a second TNBC trial is being planned with the I‑SPY 2 consortium, subject to additional capital. In December 2024, Galera acquired Nova Pharmaceuticals and issued 119,318 Series B non‑voting convertible preferred shares (each convertible into 1,000 common shares if approved), and completed a $2.9 million private placement at $0.065 per share or pre‑funded warrant. Common shares outstanding were 75,462,390 as of November 12, 2025.
Galera Therapeutics (GRTX) reported that Blackstone executed a notice of assignment acknowledging Galera’s assignment of the Amended and Restated Purchase and Sale Agreement to Biossil Inc. and agreeing to look solely to Biossil for all obligations of the “Seller” under that agreement.
This step follows Galera’s Asset Purchase and Sale Agreement under which it sold all of its dismutase mimetic assets, including avasopasem (GC4419) and rucosopasem (GC4711), to Biossil, with Biossil assuming liabilities related to those assets. The notice of assignment was executed after the transaction and is filed as Exhibit 10.1.
Galera Therapeutics (GRTX) agreed to sell its avasopasem (GC4419), rucosopasem (GC4711), and other dismutase mimetic assets to Biossil Inc. under an Asset Purchase and Sale Agreement, as amended.
The purchase price includes an upfront payment of $3,500,000 and potential future regulatory milestones, commercial milestones, and contingent value rights of up to $105,000,000 in aggregate. Biossil also agreed to assume all further rights and obligations of Galera under the Amended and Restated Purchase and Sale Agreement dated November 14, 2018, with Clarus IV Galera Royalty AIV, L.P., which is affiliated with Blackstone Life Sciences.
The agreement includes customary representations, warranties, and covenants, with certain confidentiality, indemnification, and payment provisions surviving closing. Galera plans to file the full agreement as an exhibit to its next Form 10-Q.
FAQ
What is the current stock price of Galera Therapeutics (GRTX)?
What is the market cap of Galera Therapeutics (GRTX)?
